MYDA Advisors’s bluebird bio BLUE Stock Holding History

MYDA Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-309	Closed	-$712K	–	123
2017 Q4	$712K	Buy	+309	New	+$627K	0.32%	75

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MYDA Advisors's BLUE Position: Q1 2018 in Review

MYDA Advisors sold out of bluebird bio (BLUE) in Q1 2018, closing a stake of 309 shares — an estimated $712K sold.

MYDA Advisors first reported a position in BLUE in Q4 2017 and held it in 1 quarter. The position peaked at $712K in Q4 2017. 303 funds tracked by Wall St. Rank hold BLUE as of Q1 2018.

MYDA Advisors reported no remaining bluebird bio position as of Q1 2018 after selling out during the quarter.
MYDA Advisors sold 309 bluebird bio shares in Q1 2018, an estimated $712K.
MYDA Advisors first reported a position in bluebird bio in Q4 2017 and held it in 1 quarter.
MYDA Advisors's bluebird bio position peaked at $712K in Q4 2017.
303 funds tracked by Wall St. Rank held bluebird bio as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.